BACKGROUND: The different types of pulmonary fibrosis are a subgroup of the interstitial lung diseases (ILDs). They are associated with a chronic and often progressive course. METHODS: This review is based on pertinent publications retrieved by a selective search in the EMBASE and PubMed databases, with an emphasis on articles published from 2000 to 2020. RESULTS: The most common type of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). Among other relevant types, the most important ones are fibrosing hypersensitivity pneumonitis (fHP) and ILDs associated with systemic diseases, all of which are rare and generally carry a poor prognosis. The essential prerequisite to accurate diagnosis is aninterdisciplinary approach, taking account of the clinical, histological, and radiological aspects. The main complications of pulmonary fibrosis are acute exacerbations and pulmonary hypertension; comorbidities are also of prognostic relevance. Treatment of pulmonary fibrosis depends on the subtype and clinical behavior. For IPF, antifibrotic therapy is indicated; fHP, on the other hand, is mainly treated by antigen avoidance and immune modulation. The predominant mode of treatment for systemic disease-associated pulmonary fibrosis is immune suppression. Antifibrotic agents can also be useful in the treatment of other types of progressivepulmonary fibrosis besides IPF. CONCLUSION: The differential diagnosis of pulmonary fibrosis, though complex, is clinically essential, as different types of pulmonary fibrosis are treated differently.
BACKGROUND: The different types of pulmonary fibrosis are a subgroup of the interstitial lung diseases (ILDs). They are associated with a chronic and often progressive course. METHODS: This review is based on pertinent publications retrieved by a selective search in the EMBASE and PubMed databases, with an emphasis on articles published from 2000 to 2020. RESULTS: The most common type of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). Among other relevant types, the most important ones are fibrosing hypersensitivity pneumonitis (fHP) and ILDs associated with systemic diseases, all of which are rare and generally carry a poor prognosis. The essential prerequisite to accurate diagnosis is aninterdisciplinary approach, taking account of the clinical, histological, and radiological aspects. The main complications of pulmonary fibrosis are acute exacerbations and pulmonary hypertension; comorbidities are also of prognostic relevance. Treatment of pulmonary fibrosis depends on the subtype and clinical behavior. For IPF, antifibrotic therapy is indicated; fHP, on the other hand, is mainly treated by antigen avoidance and immune modulation. The predominant mode of treatment for systemic disease-associated pulmonary fibrosis is immune suppression. Antifibrotic agents can also be useful in the treatment of other types of progressivepulmonary fibrosis besides IPF. CONCLUSION: The differential diagnosis of pulmonary fibrosis, though complex, is clinically essential, as different types of pulmonary fibrosis are treated differently.
Authors: Maurits Demedts; Juergen Behr; Roland Buhl; Ulrich Costabel; Richard Dekhuijzen; Henk M Jansen; William MacNee; Michiel Thomeer; Benoit Wallaert; François Laurent; Andrew G Nicholson; Eric K Verbeken; Johny Verschakelen; Christopher D R Flower; Frédérique Capron; Stefano Petruzzelli; Paul De Vuyst; Jules M M van den Bosch; Eulogio Rodriguez-Becerra; Giuseppina Corvasce; Ida Lankhorst; Marco Sardina; Mauro Montanari Journal: N Engl J Med Date: 2005-11-24 Impact factor: 91.245
Authors: Lauren K Troy; Christopher Grainge; Tamera J Corte; Jonathan P Williamson; Michael P Vallely; Wendy A Cooper; Annabelle Mahar; Jeffrey L Myers; Simon Lai; Ellie Mulyadi; Paul J Torzillo; Martin J Phillips; Helen E Jo; Susanne E Webster; Qi T Lin; Jessica E Rhodes; Matthew Salamonsen; Jeremy P Wrobel; Benjamin Harris; Garrick Don; Peter J C Wu; Benjamin J Ng; Christopher Oldmeadow; Ganesh Raghu; Edmund M T Lau Journal: Lancet Respir Med Date: 2019-09-29 Impact factor: 30.700
Authors: Jürgen Behr; Antje Prasse; Hubert Wirtz; Dirk Koschel; David Pittrow; Matthias Held; Jens Klotsche; Stefan Andreas; Martin Claussen; Christian Grohé; Henrike Wilkens; Lars Hagmeyer; Dirk Skowasch; Joachim F Meyer; Joachim Kirschner; Sven Gläser; Nicolas Kahn; Tobias Welte; Claus Neurohr; Martin Schwaiblmair; Thomas Bahmer; Tim Oqueka; Marion Frankenberger; Michael Kreuter Journal: Eur Respir J Date: 2020-08-13 Impact factor: 16.671
Authors: Jürgen Behr; Andreas Günther; Francesco Bonella; Klaus Geißler; Dirk Koschel; Michael Kreuter; Antje Prasse; Nicolas Schönfeld; Helmut Sitter; Joachim Müller-Quernheim; Ulrich Costabel Journal: Pneumologie Date: 2018-01-16